7 completed, 5 recruiting, 2 not yet recruiting, 1 terminated. 10 Phase 2, 6 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Recruiting 4, Not yet recruiting 2 |
| Phase 1 | 6 | Recruiting 3, Completed 2, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Clemastine: new trials by email Literature Review of Clemastine trials Research Report on Clemastine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy Clemastine Fumarate, Placebo - Demyelinating Diseases, Demyelination; Corpus Callosum | Phase 1 / Phase 2 | Not yet recruiting | University of California, San Francisco | 44 | 2026-09-15 | 2026-03-11 |
| Neonatal White Matter Injury Trial (WRAP) Clemastine fumarate - White Matter Injury, Brain Injury, Fetus and Neonate | Phase 1 | Recruiting | Bridget LaMonica Ostrem, M.D., Ph.D. | 24 | 2026-07-26 | 2026-07-28 |
| Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression Clemastine Fumarate, Placebo - Depression | Phase 2 | Recruiting | University of Illinois at Chicago | 80 | 2025-12-10 | 2026-06-30 |
| A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound - Central Auditory Processing Disorder, Hearing Impaired (Partially) | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 344 | 2025-03-31 | 2026-04-30 |
| Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity clemastine (8 mg/day), Placebo - Schizophrenia | Phase 2 | Not yet recruiting | LMU Klinikum | 90 | 2024-04-01 | 2024-03-20 |
| Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome Clemastine Fumarate Tablets, corn starch tablets - Williams Syndrome, Child | Phase 2 | Completed | Qilu Hospital of Shandong University | 28 | 2024-03-20 | 2026-03-19 |
| Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy Clemastine Fumarate, Placebo - Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 74 | 2023-08-01 | 2026-07-02 |
| Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis Clemastine Fumarate, Placebo - Multiple Sclerosis, Internuclear Ophthalmoplegia | Phase 3 | Terminated | Amsterdam UMC, location VUmc | 47 | 2022-08-30 | 2026-05-06 |
| CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy Metformin and clemastine in combination, Placebo - Multiple Sclerosis | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 70 | 2022-03-08 | 2025-12-11 |
| Clemastine in Cardiovascular Surgery Clemastine, Saline Solution - Efficacy and Safety | Not applicable | Completed | Chinese Academy of Medical Sciences, Fuwai Hospital | 100 | 2019-02-20 | 2020-01-13 |
| Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) Clemastine, Placebo - Optic Neuritis | Phase 2 | Recruiting | University of California, San Francisco | 90 | 2017-02-28 | 2026-03-11 |
| Effect of Clemastine Fumarate on Color Vision in Healthy Controls Clemastine fumarate - Healthy Subjects | Phase 1 | Completed | University of California, San Francisco | 23 | 2016-04-01 | 2016-11-03 |
| Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis Clemastine, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Completed | University of California, San Francisco | 50 | 2014-01-01 | 2025-09-17 |
| Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria Omalizumab 75-375 mg, Placebo to omalizumab, Loratadine - Chronic Urticaria | Phase 2 | Completed | Novartis | 49 | 2007-05-01 | 2011-10-21 |
| To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories), Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.) - Allergy | Phase 1 | Completed | Sandoz | 36 | 1989-12-01 | 2017-03-28 |
Multiple Sclerosis (4) · Multiple Sclerosis, Relapsing-Remitting (2) · Anaphylaxis (1) · Auditory Diseases, Central (1) · Brain Injuries (1) · Chronic Urticaria (1) · Demyelinating Diseases (1) · Depression (1) · Epilepsy, Idiopathic Generalized (1) · Eye Pain (1) · Hearing Disorders (1) · Hearing Loss (1) · Hearing Loss, Hidden (1) · Hearing Loss, Noise-Induced (1) · Hearing Loss, Sensorineural (1)
University of California, San Francisco (5) · Amsterdam UMC, location VUmc (1) · Bridget LaMonica Ostrem, M.D., Ph.D. (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Chinese Academy of Medical Sciences, Fuwai Hospital (1) · LMU Klinikum (1) · Novartis (1) · Qilu Hospital of Shandong University (1) · Sandoz (1) · University of Colorado, Denver (1) · University of Illinois at Chicago (1)
United States (8) · China (2) · Germany (1) · Netherlands (1) · United Kingdom (1)
Ari Green, MD, MCR (2) · Achim Klug, PhD (1) · Ari J Green, MD (1) · Ari J Green, MD, MCR (1) · Ari J. Green, MD, MCR (1) · Axel Petzold, Dr. (1) · Bridget Ostrem, MD, PhD (1) · James C. Kisicki, M.D. (1) · Jia Shi, M.D. (1) · Nick Cunniffe (1) · Samuel A Budoff, PhD, MS (1)
PMID 29029896, PMID 35710320, PMID 38296293, PMID 41361285
1DP2NS148743-01 (1)